In the relentless struggle against cancer, one of the most debilitating complications that continue to perplex clinicians and researchers alike is cancer cachexia—a multifactorial syndrome characterized by severe body weight, muscle, and fat loss, dramatically impairing patient quality of life and survival outcomes. The recent review by Thakur and Chorawala, published in Medical Oncology, charts an illuminating course through novel therapeutic avenues aimed at preventing cancer cachexia, focusing particularly on the roles of metronomic chemotherapy and drug repurposing strategies. Their comprehensive analysis signals a paradigm shift in how the oncology community might approach cachexia prevention, injecting fresh hope into an area long constrained by therapeutic limitations.
Metronomic chemotherapy, distinct from traditional cytotoxic regimens, administers chemotherapeutic agents at comparatively low doses on a frequent schedule without extended breaks. Unlike the conventional maximum tolerated dose (MTD) protocols, this strategy minimizes acute toxicity and exploits antiangiogenic and immunomodulatory effects. Thakur and Chorawala’s review underscores the mechanistic rationale behind metronomic schedules, highlighting how sustained vascular normalization and immune system modulation could directly counteract the systemic inflammatory milieu driving cachexia progression. This subtle yet sustained therapeutic pressure limits tumor growth and disrupts pathological interactions between cancer and host metabolism, offering a novel checkpoint in cachexia’s pathogenesis.
The authors delve deeply into the molecular pathways disrupted in cachectic patients, such as the dysregulation of inflammatory cytokines including TNF-alpha, IL-6, and IFN-gamma, and how metronomic chemotherapy modulates these mediators. They describe evidence suggesting that such low-dose, frequent chemotherapy suppresses these cytokines’ secretion, mitigating muscle wasting and fat depletion. Furthermore, by attenuating chronic inflammation and improving the tumor microenvironment’s stability, metronomic therapy may recalibrate the host’s anabolic-catabolic balance, staving off the catastrophic tissue breakdown typical in cachectic patients.
Parallel to metronomic chemotherapy, the review examines the burgeoning field of drug repurposing—a strategy that identifies existing pharmacological agents, originally approved for other indications, as viable cachexia therapeutics. This approach leverages known safety profiles and accelerates clinical application, bypassing the lengthy phases of novel drug development. Thakur and Chorawala notably explore how drugs such as beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, and selective serotonin reuptake inhibitors (SSRIs) may influence cachexia’s multifaceted pathways. The synergy of repurposed drugs with chemotherapy, particularly when administered metronomically, emerges as a promising combinatorial strategy for cachexia prevention.
A critical facet elaborated in the review involves the role of metabolic reprogramming in cancer cachexia. The authors discuss how tumors drive systemic metabolic alterations, including increased energy expenditure and proteolysis, propelling the syndrome. Therapeutic interventions focusing on metabolic modulation, either through pharmacological agents or dietary interventions bolstered by metronomic chemotherapy’s cytostatic effects, can restore some degree of metabolic homeostasis. Such restoration could, in turn, slow or halt muscle wasting and adipose tissue loss, which are the hallmarks of cachexia.
Advances in molecular oncology have unveiled key biomarkers predictive of cachexia development, a theme meticulously covered in the review. Early identification of at-risk patients through molecular signatures—including elevated proinflammatory cytokines and muscle degradation markers—allows for timely therapeutic intervention. Thakur and Chorawala suggest that integrating these biomarkers into clinical decision-making for metronomic chemotherapy scheduling or drug repurposing regimens could personalize cachexia management, optimizing effectiveness while minimizing unnecessary toxicity.
The review also critically analyzes current clinical trials investigating metronomic chemotherapy’s efficacy in cachexia prevention. Although data remain preliminary, early-phase trials report improved muscle mass retention, enhanced functional status, and better overall survival in specific cancer subsets. Furthermore, by attenuating tumor progression and systemic inflammation, metronomic chemotherapy shifts the clinical focus from symptom palliation to disease modification and cachexia mitigation. This distinction marks a significant advancement in therapeutic goals.
In parallel, emerging preclinical studies on drug repurposing strategies demonstrate encouraging results. The authors highlight studies showcasing ACE inhibitors’ role in attenuating muscle fibrosis and SSRIs’ potential in modulating appetite and serotonergic pathways implicated in cachexia-associated anorexia. When combined with chemotherapeutic agents, these drugs may yield additive or synergistic effects, reinforcing the need for well-structured clinical trials to validate these efficacies and safety profiles in cachectic cancer patients.
A pivotal challenge addressed in the review is the heterogeneity intrinsic to cancer cachexia, stemming from tumor type, genetic background, and treatment history, complicating one-size-fits-all approaches. Thakur and Chorawala argue for stratified medicine frameworks that utilize metronomic dosing and repurposed drugs tailored to individual patient profiles. This approach would maximize therapeutic impact on cachexia pathways while concurrently managing the underlying malignancy.
Moreover, the interaction between the gut microbiome and cancer cachexia emerges as a fascinating frontier in this review. Altered microbial populations influence systemic inflammation and metabolism, potentially modifiable through metronomic chemotherapy’s immunomodulatory effects or specific repurposed agents with known microbiota interactions. Future therapeutic algorithms might integrate microbiome modulation to complement chemotherapy and pharmacological interventions, creating a multifaceted battleground against cachexia.
From a pharmacokinetic perspective, metronomic chemotherapy presents unique benefits and challenges. Its frequent administration maintains consistent plasma drug levels, reducing peaks and troughs that often precipitate toxicity or suboptimal therapeutic windows. The review thoroughly examines these dynamics, emphasizing how understanding drug absorption, distribution, metabolism, and elimination under continuous low dosing informs optimal scheduling, dosing, and combination strategies with repurposed drugs.
Crucially, patient-centric outcomes, such as quality of life, functional independence, and symptom burden, form the evaluative cornerstone for cachexia therapeutics. The authors underscore that beyond mere survival extension, preventing cachexia translates into tangible improvements in patient well-being, physical resilience, and treatment tolerability. Metronomic protocols and strategic drug repurposing aim to uphold these values, merging molecular insights with clinical priorities.
Integration of advanced imaging and molecular diagnostics further refines cachexia management as discussed in the review. Techniques including PET scans, MRI for muscle mass quantification, and molecular profiling enable responsive adjustments to therapy. The authors stress that dynamic monitoring through these technologies can guide metronomic chemotherapy cycles and repurposed drug utilization, ensuring maximal benefit while curbing adverse effects.
In conclusion, Thakur and Chorawala’s review articulates a compelling narrative of transformation in cancer cachexia management. The combined utilization of metronomic chemotherapy and drug repurposing not only addresses cachexia pathophysiology more holistically but harnesses existing therapeutic modalities innovatively. Their synthesis of basic science, translational research, and clinical data forms a blueprint for future investigations, advocating for an integrated, patient-tailored approach.
This evolving landscape signifies a breakthrough, transcending the traditional palliative mindset toward proactive prevention and reversal of cancer cachexia. As oncology strives for precision and personalization, metronomic chemotherapy and drug repurposing stand at the forefront, offering new hope in ameliorating one of cancer’s most pernicious complications.
Subject of Research: Cancer cachexia prevention strategies involving metronomic chemotherapy and drug repurposing.
Article Title: The evolving landscape of cancer cachexia prevention: A review of metronomic chemotherapy and drug repurposing strategies.
Article References:
Thakur, A., Chorawala, M.R. The evolving landscape of cancer cachexia prevention: A review of metronomic chemotherapy and drug repurposing strategies. Med Oncol 43, 40 (2026). https://doi.org/10.1007/s12032-025-03166-6
Image Credits: AI Generated
